NCT01470287已完成3 期
A Phase-III, Single Arm, Multi-Center, Open-Label Study to Assess the Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent Vaccine (DTwP-Hib-HepB Vaccine) When Administered to Indian Infants at 6, 10, and 14 Weeks of Age
Novartis Vaccines3 个研究点 分布在 1 个国家目标入组 175 人开始时间: 2011年12月最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 175
- 试验地点
- 3
- 主要终点
- Seroprotection rate one month after the last dose of vaccine administration
研究概览
简要总结
This study will evaluate immunogenicity, safety and tolerability of fully liquid pentavalent vaccine (DTwP-Hib-HepB Vaccine) in infants 6-8 weeks of age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 42 Days 至 64 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects ≥ 42 days to ≤ 64 days of age.
- •Written informed consent obtained from either parents/ legal guardian after the nature of the study has been explained according to local regulatory requirements
排除标准
- •Subjects whose parents or legal guardians are unwilling or unable to give written informed consent to participate in the study.
- •History of previous immunization with a vaccine containing any of the 5 antigen components of investigational vaccine.
- •History of anaphylactic shock(immediate hypersensitivity reactions), urticaria or other allergic reactions after previous vaccination or known hypersensitivity to any vaccine component.
- •Administration of parenteral immunoglobulin preparation and/or blood products since birth.
结局指标
主要结局
Seroprotection rate one month after the last dose of vaccine administration
时间窗: One month after last vaccination
次要结局
- Seroprotection rate and GMCs one month after the last vaccine administration(One month after last vaccination)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in KoreaMeningococcal DiseaseMeningococcal MeningitisNCT01274897Novartis Vaccines450
已完成
3 期
Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult VolunteersInfluenzaNCT01987011Green Cross Corporation420
已完成
不适用
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.SARS CoV 2 InfectionNCT05303402Hipra Scientific, S.L.U241
已完成
3 期
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of AgeRespiratory Syncytial Virus InfectionsNCT05169905GlaxoSmithKline9
已完成
3 期
A Study of 2 Doses of VAQTA™ in Healthy Children 12 to 23 Months of Age (V251-069)Hepatitis A Virus InfectionNCT00835380Merck Sharp & Dohme LLC80